Develops novel drugs addressing unmet needs in inflammatory diseases, fibrosis, and pain management.
180 Life Sciences Corp., a clinical-stage biotechnology company based in Palo Alto, California, is dedicated to developing innovative therapeutics targeting chronic pain, inflammation, fibrosis, and various inflammatory diseases. The company's robust product development platforms include a focus on fibrosis and Anti-TNF therapies, currently advancing through Phase IIb clinical trials. These initiatives aim to address significant unmet medical needs by targeting pathways involved in fibrotic diseases and modulating tumor necrosis factor (TNF) activity.
In addition to its fibrosis and Anti-TNF platform, 180 Life Sciences is actively exploring Synthetic Cannabidiol (CBD) Analogs, a promising area in preclinical trials. These synthetic derivatives of CBD hold potential for therapeutic appllications across a range of conditions. Furthermore, the company is advancing its a7nAChR platform, which targets the alpha 7 nicotinic acetylcholine receptor to suppress immune responses,, with the goal of developing novel treatments for immune related disorders.
Established in 2016, 180 Life Sciences leverages cutting-edge biomedical research and strategic partnerships to drive its pipeline forward. With a commitment to scientific excellence and patient-centric innovation, the company continues to expand its capabilities and explore new avenues in biotechnology, positioning itself at the forefront of therapeutic advancements in chronic diseases.